Castle Biosciences gets $11.7M Series F for cancer diagnostics
In order to fuel sales of its cancer diagnostics, Texas startup Castle Biosciences just raised the first, $11.7 million tranche of a $20 million Series D.
Castle Biosciences commercializing tests for orphan cancers, raising $11.8M
Texas cancer diagnostics company Castle Biosciences plans to expand the clinical availability of its tests that assess “rare and underserved cancers,” particularly one for cutaneous melanoma. It has wrapped up an $11.8 million round to do so, the company said. The round was led by new investor HealthQuest Capital; existing investors Mountain Group Capital and Affiliates, Longfellow […]
presented by
Market Trends to Watch for Health Systems and Their Specialty Pharmacies
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.